{"id":"https://openalex.org/W2046670565","doi":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","title":"The Critical Role of Risk-Benefit Assessments in Cancer Prevention","display_name":"The Critical Role of Risk-Benefit Assessments in Cancer Prevention","publication_year":2005,"publication_date":"2005-02-01","ids":{"openalex":"https://openalex.org/W2046670565","doi":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","mag":"2046670565","pmid":"https://pubmed.ncbi.nlm.nih.gov/15734949"},"language":"en","primary_location":{"id":"doi:10.1158/1055-9965.epi-14-2-eda","doi":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","pdf_url":"https://aacrjournals.org/cebp/article-pdf/14/2/297/2263672/297-298.pdf","source":{"id":"https://openalex.org/S8391440","display_name":"Cancer Epidemiology Biomarkers & Prevention","issn_l":"1055-9965","issn":["1055-9965","1538-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Epidemiology, Biomarkers & Prevention","raw_type":"journal-article"},"volume":null,"type":"editorial","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/cebp/article-pdf/14/2/297/2263672/297-298.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015008352","display_name":"Ernest T. Hawk","orcid":"https://orcid.org/0000-0002-9062-7338","observed_orcids":["https://orcid.org/0000-0002-9062-7338"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ernest Hawk","raw_affiliation_strings":["Gastrointestinal and Other Research Group, Division of Cancer Prevention, The National Cancer Institute, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gastrointestinal and Other Research Group, Division of Cancer Prevention, The National Cancer Institute, Bethesda, Maryland","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5080636708","display_name":"Jaye L. Viner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jaye L. Viner","raw_affiliation_strings":["Gastrointestinal and Other Research Group, Division of Cancer Prevention, The National Cancer Institute, Bethesda, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gastrointestinal and Other Research Group, Division of Cancer Prevention, The National Cancer Institute, Bethesda, Maryland","institution_ids":["https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140884"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"2","first_page":"297","last_page":"298"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.5547000169754028,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.5547000169754028,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.20559999346733093,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.02800000086426735,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-prevention","display_name":"cancer prevention","score":0.8059999942779541},{"id":"https://openalex.org/keywords/chemoprevention","display_name":"chemoprevention","score":0.9129999876022339},{"id":"https://openalex.org/keywords/risk-benefit-assessment","display_name":"risk-benefit assessment","score":0.9959999918937683},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6790000200271606},{"id":"https://openalex.org/keywords/rofecoxib","display_name":"rofecoxib","score":0.6510000228881836},{"id":"https://openalex.org/keywords/cox-2-inhibitors","display_name":"COX-2 inhibitors","score":0.871999979019165},{"id":"https://openalex.org/keywords/nonsteroidal-anti-inflammatory-drugs","display_name":"nonsteroidal anti-inflammatory drugs","score":0.9259999990463257},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.9580000042915344},{"id":"https://openalex.org/keywords/tamoxifen","display_name":"tamoxifen","score":0.9340000152587891},{"id":"https://openalex.org/keywords/finasteride","display_name":"finasteride","score":0.9959999918937683},{"id":"https://openalex.org/keywords/aspirin","display_name":"aspirin","score":0.996999979019165},{"id":"https://openalex.org/keywords/beta-carotene","display_name":"beta-carotene","score":0.8080000281333923},{"id":"https://openalex.org/keywords/vitamin-e","display_name":"vitamin E","score":0.9559999704360962},{"id":"https://openalex.org/keywords/regulatory-oversight","display_name":"regulatory oversight","score":0.5860000252723694},{"id":"https://openalex.org/keywords/patient-safety","display_name":"patient safety","score":0.5839999914169312},{"id":"https://openalex.org/keywords/carcinogenesis","display_name":"carcinogenesis","score":0.6340000033378601},{"id":"https://openalex.org/keywords/interpretation-of-trial-results","display_name":"trial interpretation","score":0.31299999356269836}],"concepts":[{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.5269347429275513},{"id":"https://openalex.org/C12174686","wikidata":"https://www.wikidata.org/wiki/Q1058438","display_name":"Risk assessment","level":2,"score":0.446671724319458},{"id":"https://openalex.org/C2780234812","wikidata":"https://www.wikidata.org/wiki/Q1787013","display_name":"Cancer prevention","level":3,"score":0.43438538908958435},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3845834732055664},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.3390341103076935},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2925029397010803},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.2349691390991211},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.11602076888084412},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.09462139010429382}],"mesh":[{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016588","descriptor_name":"Anticarcinogenic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1055-9965.epi-14-2-eda","doi":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","pdf_url":"https://aacrjournals.org/cebp/article-pdf/14/2/297/2263672/297-298.pdf","source":{"id":"https://openalex.org/S8391440","display_name":"Cancer Epidemiology Biomarkers & Prevention","issn_l":"1055-9965","issn":["1055-9965","1538-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Epidemiology, Biomarkers & Prevention","raw_type":"journal-article"},{"id":"pmid:15734949","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15734949","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","raw_type":"Editorial"}],"best_oa_location":{"id":"doi:10.1158/1055-9965.epi-14-2-eda","doi":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1055-9965.epi-14-2-eda","pdf_url":"https://aacrjournals.org/cebp/article-pdf/14/2/297/2263672/297-298.pdf","source":{"id":"https://openalex.org/S8391440","display_name":"Cancer Epidemiology Biomarkers & Prevention","issn_l":"1055-9965","issn":["1055-9965","1538-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Epidemiology, Biomarkers & Prevention","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2046670565.pdf","grobid_xml":"https://content.openalex.org/works/W2046670565.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4232986616","https://openalex.org/W2322301587","https://openalex.org/W2083498895","https://openalex.org/W2031405335","https://openalex.org/W2120087849","https://openalex.org/W2800255682","https://openalex.org/W2080974546","https://openalex.org/W2327276798","https://openalex.org/W2082764531","https://openalex.org/W2260549328"],"abstract_inverted_index":{"Controversy":[0],"is":[1,207,369,1024,1148,1188],"building":[2],"around":[3],"agent":[4,64,145,522,574,676,728],"development":[5,65,704],"for":[6,66,147,367,386,393,492,528,552,708,771,804,872,965,1014,1036,1042,1223],"cancer":[7,67,73,97,131,148,160,203,230,278,359,387,482,493,553,721,955,1131,1161,1210],"prevention.":[8,68],"The":[9,69,613,667,927,946],"withdrawal":[10],"of":[11,24,42,55,72,128,177,181,198,228,276,288,301,304,320,333,338,374,380,407,454,477,507,521,573,585,589,611,629,640,657,670,705,711,720,747,774,806,834,845,857,875,918,949,980,1028,1039,1083,1095,1103,1110,1143,1165,1216,1227],"rofecoxib":[12],"(Vioxx,":[13],"Merck)":[14],"from":[15,329,694,1067],"the":[16,56,102,126,165,196,225,274,330,336,365,405,445,450,474,505,597,655,703,709,744,832,855,873,880,960,1025,1037,1074,1128,1138,1166,1200,1224],"market":[17],"and":[18,28,38,110,116,187,200,217,280,323,335,350,356,377,438,460,470,524,532,587,600,644,673,723,730,739,809,829,860,886,904,907,924,957,983,1050,1071,1092,1106,1109,1133,1145,1207,1220],"safety":[19,310,439,677],"concerns":[20,212,674,933],"raised":[21],"by":[22,204,231,684,944,977,1006],"studies":[23,632],"other":[25,351],"cyclooxygenase-2-selective":[26],"inhibitors":[27],"an":[29,239,607,638,735,1150],"over-the-counter":[30],"nonsteroidal":[31,43],"anti-inflammatory":[32,44],"drug":[33],"have":[34,263,850,869,902,1002],"alarmed":[35],"patients,":[36],"physicians,":[37],"regulatory":[39,112],"authorities.":[40],"Evidence":[41],"drug\u2013associated":[45],"cardiovascular":[46,1022],"toxicity\u2014of":[47],"relatively":[48],"low":[49],"frequency":[50],"but":[51,233,249,605,753],"significant":[52,402],"magnitude\u2014reminds":[53],"us":[54],"critical":[57,516],"role":[58],"that":[59,257,382,440,546,715,991],"risk-benefit":[60,166],"assessments":[61,155],"play":[62],"in":[63,77,107,114,130,141,159,168,241,358,404,436,481,484,512,530,540,563,576,649,727,763,863,973,1016,1021,1108,1192,1209],"placebo-controlled":[70],"design":[71],"prevention":[74,132,149,313,360,486,923,989,1020,1070,1132,1147,1211],"trials":[75,180,289,314,395,487,502,593,648,660,682],"explains":[76],"part":[78],"why":[79],"these":[80,190,349,463,631,846],"toxicities":[81,908],"came":[82],"to":[83,93,96,104,121,211,223,272,309,317,342,399,433,444,495,517,681,742,783,901,916,987,1069,1174,1176,1182,1199],"light":[84],"only":[85,898],"recently.":[86],"Although":[87,193,831,1127],"this":[88,122,1004,1029,1119],"could":[89],"dampen":[90],"industry's":[91],"willingness":[92],"commit":[94],"resources":[95],"prevention,":[98,161,931],"it":[99,206,234,250,340,1179,1196],"also":[100,236,1197],"has":[101,1114],"potential":[103],"stimulate":[105],"creativity":[106],"clinical":[108,312,345,485,556,772,827,1193,1228],"research":[109,620,642,1201],"transform":[111],"oversight":[113],"productive":[115],"meaningful":[117],"ways.":[118],"Our":[119],"response":[120],"challenge":[123],"will":[124,914],"dictate":[125],"pace":[127],"progress":[129,480],"research.The":[133],"tension":[134],"between":[135,884,1130],"assuring":[136],"patient":[137],"safety\u2014our":[138],"main":[139],"concern":[140],"investigational":[142,419,426,537],"trials\u2014and":[143],"proving":[144],"efficacy":[146,437,523,575],"poses":[150],"distinct":[151],"developmental":[152,191,1221],"challenges.":[153,192],"Safety":[154],"are":[156,315,383,388,396,515,634,890,909,941],"inherently":[157],"difficult":[158],"which":[162],"must":[163,690],"balance":[164],"ratio":[167],"a":[169,173,286,302,362,401,412,466,567,840,1124,1154],"specific":[170],"group":[171,414],"at":[172,361,384,490,549,892,935,959,1137],"presumed\u2014although":[174],"still":[175],"probabilistic\u2014risk":[176],"cancer.":[178],"Positive":[179],"compounds,":[182],"such":[183,821,1088],"as":[184,564,566,822,854,1089,1099,1184],"tamoxifen,":[185],"finasteride,":[186],"aspirin,":[188],"illustrate":[189],"tamoxifen":[194],"reduces":[195,245],"risk":[197,275,385,491,499,551,939,1040,1086,1144],"invasive":[199],"noninvasive":[201],"breast":[202],"\u223c50%,":[205],"rarely":[208],"used":[209],"owing":[210,494],"regarding":[213],"treatment-related":[214],"uterine":[215],"cancers":[216],"thrombotic":[218],"events.":[219,749,1018],"Finasteride":[220],"was":[221,235,269,1121],"shown":[222,271],"reduce":[224],"period":[226],"prevalence":[227],"prostate":[229],"25%,":[232],"associated":[237],"with":[238,290,542,558],"increase":[240,273],"higher-grade":[242],"cancers.":[243],"Aspirin":[244],"recurrent":[246],"colorectal":[247],"adenomas,":[248],"conveys":[251],"hemorrhagic":[252],"risks.":[253],"Even":[254],"nutritional":[255],"compounds":[256,527],"were":[258],"once":[259],"considered":[260],"benign":[261],"interventions":[262],"checkered":[264],"profiles.":[265],"For":[266,535,698,766],"example,":[267,536,699,767],"\u03b2-carotene":[268],"actually":[270],"lung":[277],"incidence":[279,956],"mortality":[281,295,958,1113],"among":[282,296],"smokers.":[283],"More":[284],"recently,":[285],"meta-analysis":[287],"vitamin":[291,305],"E":[292,306],"suggested":[293],"increased":[294],"people":[297],"using":[298],"high":[299,550,609],"doses":[300],"subset":[303],"supplements.In":[307],"addition":[308],"issues,":[311],"subject":[316],"varying":[318],"interpretations":[319],"their":[321,971,981],"short-term":[322],"long-term":[324,603],"significance.":[325],"This":[326,985,1186],"uncertainty":[327],"derives":[328],"probabilistic":[331,891],"nature":[332],"carcinogenesis":[334,376,788,1206],"length":[337],"time":[339,363,410],"takes":[341],"observe":[343],"\u201chard\u201d":[344],"end":[346,458,471,713,819,837],"points.":[347],"Ironically,":[348],"obstacles":[352],"limit":[353],"commercial":[354],"interest":[355],"investment":[357],"when":[364],"demand":[366,678],"chemoprevention":[368],"growing.":[370],"Nonetheless,":[371],"increasing":[372,641],"understanding":[373,719],"molecular":[375],"growing":[378,668],"numbers":[379],"individuals":[381,514,541,934],"creating":[389],"exciting":[390],"new":[391,757],"opportunities":[392,643],"chemoprevention.Intervention":[394],"typically":[397,582,942],"designed":[398],"show":[400],"difference":[403],"number":[406,669,746],"events":[408,889,1044],"over":[409,675],"within":[411,879],"particular":[413],"(i.e.,":[415,615],"before":[416],"versus":[417,428],"after":[418],"treatment)":[420],"or":[421,510,579,651,664,758,1053],"across":[422],"different":[423,759],"groups":[424,581,653],"(e.g.,":[425,781,1045],"treatment":[427,874,1038,1068,1134],"standard":[429],"care).":[430],"In":[431,637,687,791],"order":[432],"identify":[434],"differences":[435],"might":[441,716],"be":[442,899],"ascribed":[443],"experimental":[446],"regimen,":[447],"researchers":[448,1063],"exploit":[449],"three":[451,464],"cardinal":[452],"elements":[453],"trial":[455,813,1218],"design:":[456],"participants,":[457,619],"points,":[459,820],"agents.":[461],"Among":[462],"elements,":[465],"focus":[467,856],"on":[468,504,692,1153],"participants":[469,562,586],"points":[472,714,838],"offers":[473],"greatest":[475],"likelihood":[476],"accelerating":[478],"near-term":[479],"prevention.Participants":[483],"include":[488],"persons":[489],"endogenous":[496],"and/or":[497],"exogenous":[498],"factors.":[500],"Preliminary":[501],"focused":[503],"biology":[506,722],"neoplastic":[508,748,888],"initiation":[509],"progression":[511],"high-risk":[513],"detecting":[518],"early":[519,885],"signals":[520],"prioritizing":[525],"lead":[526],"testing":[529],"larger":[531],"longer-term":[533],"trials.":[534,697],"agents":[538,913],"tested":[539],"germ":[543],"line":[544],"mutations":[545],"place":[547],"them":[548],"may":[554,594,1135],"achieve":[555],"goals":[557],"fewer":[559],"than":[560,761,769,795,937,1012,1058],"100":[561],"little":[565],"few":[568],"months.":[569],"By":[570,1031],"contrast,":[571],"demonstration":[572,1027],"more":[577,662,693],"heterogeneous":[578],"lower-risk":[580],"requires":[583],"thousands":[584],"years":[588],"observation.":[590],"These":[591],"broad-scale":[592],"better":[595,1034],"reflect":[596],"general":[598],"population":[599,961],"represent":[601],"our":[602,624,695,718,1217],"goal":[604,948,1152],"require":[606,702,756],"exceptionally":[608],"level":[610],"justification.":[612],"costs":[614],"staff,":[616],"infrastructure,":[617],"available":[618],"opportunities,":[621],"and,":[622],"perhaps":[623],"most":[625,878,1189],"valuable":[626],"resource,":[627],"time)":[628],"conducting":[630],"prematurely":[633],"extraordinarily":[635],"high.":[636],"environment":[639],"limited":[645],"funding,":[646],"massive":[647],"heterogenous":[650],"low-risk":[652],"preclude":[654],"execution":[656],"many":[658,864],"smaller":[659],"involving":[661],"homogeneous":[663],"higher-risk":[665],"groups.":[666],"competing":[671],"hypotheses":[672],"renewed":[679],"commitment":[680],"informed":[683],"biological":[685],"principles.":[686],"addition,":[688,792],"we":[689,776],"insist":[691],"largest":[696],"reviewers":[700],"should":[701,777],"tissue":[706],"banks":[707],"exploration":[710],"intermediate":[712,818],"improve":[717],"permit":[724],"iterative":[725],"improvements":[726],"identification":[729],"validation.Long":[731],"follow-up":[732],"times":[733],"provide":[734,798],"effective,":[736],"although":[737],"costly":[738],"cumbersome,":[740],"approach":[741,986,1120],"acquiring":[743],"requisite":[745],"Alternative":[750],"approaches":[751],"exist,":[752],"they":[754,802],"probably":[755],"infrastructures":[760],"those":[762],"current":[764],"use.":[765],"rather":[768,1011,1057],"waiting":[770,1013],"declaration":[773],"disease,":[775],"use":[778],"sensitive":[779],"technologies":[780,968,1010],"endoscopy)":[782],"detect":[784],"disease":[785,807,1023],"earlier":[786],"during":[787],"whenever":[789],"possible.":[790],"within-person":[793],"(rather":[794],"between-person)":[796],"comparisons":[797],"important":[799,826],"efficiencies":[800],"because":[801],"control":[803],"issues":[805],"susceptibility":[808],"heterogeneity,":[810],"thereby":[811],"reducing":[812],"costs.":[814],"Finally,":[815],"realistically":[816,1008],"validated":[817,1009],"intraepithelial":[823,835,876],"neoplasia,":[824,877],"offer":[825,995],"insights":[828,1204],"efficiencies.":[830],"significance":[833],"neoplasia":[836],"remains":[839],"surprisingly":[841],"contentious":[842],"issue,":[843],"certain":[844,992],"biologically":[847],"mature":[848],"lesions":[849],"been":[851,870,1115],"definitively":[852],"established":[853],"screening,":[858],"intervention,":[859,1105],"medical":[861,922,930,988],"reimbursement":[862,1107],"settings.":[865],"Indeed,":[866,1079],">10":[867],"drugs":[868],"approved":[871],"last":[881],"5":[882],"years.Associations":[883],"late":[887,1017,1061],"best.":[893],"Therefore,":[894],"useful":[895],"chemopreventives":[896],"can":[897],"expected":[900],"relative":[903],"partial":[905],"effects,":[906],"inevitable.":[910],"Nevertheless,":[911],"effective":[912],"contribute":[915],"either":[917],"chemoprevention's":[919],"dual":[920],"objectives:":[921],"public":[925,950,1076],"health.":[926],"proximal":[928],"goal,":[929],"largely":[932],"greater":[936],"average":[938],"who":[940],"identified":[943],"screening.":[945],"distant":[947],"health":[951,1077],"involves":[952],"gains":[953],"against":[954],"level.Compelling":[962],"evidence":[963],"argues":[964],"implementing":[966,1007],"today's":[967],"while":[969],"recognizing":[970],"limitations,":[972],"each":[974],"instance":[975],"guided":[976],"serious":[978],"consideration":[979],"risks":[982],"benefits.":[984,1078],"recognizes":[990],"transitional":[993],"tools":[994,1035],"valuable,":[996],"albeit":[997],"incomplete,":[998],"solutions.":[999],"Other":[1000],"disciplines":[1001],"cleared":[1003],"hurdle":[1005],"reductions":[1015],"Clinical":[1019],"classic":[1026],"principle.":[1030],"employing":[1032],"progressively":[1033],"factors":[1041],"late-stage":[1043],"myocardial":[1046,1051],"infarction,":[1047],"cerebrovascular":[1048,1054],"accidents,":[1049],"infarction\u2013":[1052],"accident\u2013related":[1055],"death)":[1056],"exclusively":[1059],"treating":[1060],"events,":[1062],"successfully":[1064],"shifted":[1065],"emphasis":[1066],"ultimately":[1072],"achieved":[1073],"anticipated":[1075],"through":[1080],"appropriate":[1081],"adoption":[1082],"emerging":[1084],"technologies,":[1085],"factors,":[1087],"hypertension,":[1090],"hyperlipidemia,":[1091],"asymptomatic":[1093],"stages":[1094],"atherosclerosis,":[1096],"became":[1097],"accepted":[1098],"subclinical":[1100],"diseases":[1101],"worthy":[1102],"identification,":[1104],"themselves.":[1111],"Cardiovascular":[1112],"dropping":[1116],"ever":[1117],"since":[1118],"broadly":[1122],"adopted":[1123],"decade":[1125],"ago.":[1126],"distinction":[1129],"blur":[1136],"extremes":[1139],"(as":[1140],"do":[1141,1169],"concepts":[1142],"disease),":[1146],"clearly":[1149,1180],"achievable":[1151],"par":[1155],"with,":[1156],"if":[1157],"not":[1158],"preferable":[1159],"to,":[1160],"treatment.The":[1162],"central":[1163],"tenet":[1164],"Hippocratic":[1167],"oath\u2014\u201cfirst,":[1168],"no":[1170],"harm\u201d\u2014is":[1171],"generally":[1172],"assumed":[1173],"refer":[1175],"action;":[1177],"however,":[1178,1195],"applies":[1181,1198],"inaction":[1183],"well.":[1185],"principle":[1187],"readily":[1190],"evident":[1191],"practice;":[1194],"enterprise.":[1202],"Incremental":[1203],"into":[1205],"advances":[1208],"technology":[1212],"compel":[1213],"careful":[1214],"appraisal":[1215],"designs":[1219],"strategies":[1222],"next":[1225],"generation":[1226],"research.":[1229]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}